Understanding Attitudes Toward Use of Medication in Substance Abuse Treatment: A Multilevel Approach

Psychological Services

Volumn 6, Issue 1, 2009, Pages 74-84

  Fitzgerald, John ^a   McCarty, Dennis ^b  

^a PORTLAND STATE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

addiction medications; evidence based practices; substance abuse treatment

Indexed keywords

EID: 62649093043     PISSN: 15411559     EISSN: None     Source Type: Journal    
DOI: 10.1037/a0013420     Document Type: Article

References (46)

1. Amass L., Kamien J.B., and Mikulich S.K. Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet. Drug and Alcohol Dependence 58 (2000) 143-152
2. Amass L., Kamien J.B., and Mikulich S.K. Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans. Drug and Alcohol Dependence 61 (2001) 173-181
3. Amass L., Ling W., Freese T.E., Reiber C., Annon J.J., Cohen A.J., et al. Bringing buprenorphine-naloxone detoxification to community treatment programs: The NIDA Clinical Trials Network field experience. The American Journal of Addictions 13 Suppl. 1 (2004) S42-S66
4. Amato L., Davoli M., Perucci C.A., Ferri M., Faggiano F., and Mattick R.P. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: Available evidence to inform clinical practice and research. Journal of Substance Abuse Treatment 28 (2005) 321-329
5. Bryk A.S., Raudenbush S.W., and Congdon R.T. Hierarchical linear and nonlinear modeling, Version 6.01 (2005), Scientific Software International, Chicago
6. Carmen B., Angeles M., Munoz A., and Jose Maria A. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: A systematic review. Addiction 99 (2004) 811-828
7. Forman R., Bovasso G., and Woody G. Staff beliefs about addiction treatment. Journal of Substance Abuse Treatment 21 (2001) 1-9
8. Fuller B.E., Rieckmann T., McCarty D., Smith K.W., and Levine H. Adoption of naltrexone to treat alcohol dependence. Journal of Substance Abuse Treatment 28 (2005) 273-280
9. Garbutt J.C., West S.L., Carey T.S., Lohr K.N., and Crews F.T. Pharmacological treatment of alcohol dependence: A review of the evidence. JAMA: The Journal of the American Medical Association 281 (1999) 1318-1325
10. Gossop M., Marsden J., Stewart D., and Treacy S. Outcomes after methadone maintenance and methadone reduction treatments: Two-year follow-up results from the National Treatment Outcome Research Study. Drug and Alcohol Dependence 62 (2001) 255-264
11. Hox J. Multilevel analysis: Techniques and applications (2002), Erlbaum, Mahwah, NJ
12. Institute of Medicine, Lamb S., Greenlick M.R., and McCarty D. Bridging the gap between practice and research: Forging partnerships with community-based drug and alcohol treatment. Committee on Community-Based Drug Treatment (1998), National Academy Press, Washington, DC
13. Institute of Medicine. Improving the quality of health care for mental and substance use conditions: Quality of Chasm Series (2006), National Academy Press, Washington, DC
14. Johnson R.E., Chutuape M.A., Strain E.C., Walsh S.L., Stitzer M.L., and Bigelow G.E. A comparison of levomethadyl acetate, buprenorphine, and methadone for opiate dependence. New England Journal of Medicine 343 (2000) 1290-1297
15. Kaskutas L.A., Greenfield T.K., Borkman T.J., and Room J.A. Measuring treatment philosophy: A scale for substance abuse recovery programs. Journal of Substance Abuse Treatment 15 (1998) 27-36
16. Kirchmayer U., Davoli M., Verster A.D., Amato L., Ferri M., and Perucci C.A. A systematic review on the efficacy of naltrexone maintenance treatment in opioid dependence. Addiction 97 (2002) 1241-1249
17. Knudsen H.K., Ducharme L.J., and Roman P.M. The adoption of medications in substance abuse treatment: Associations with organizational characteristics and technology clusters. Drug and Alcohol Dependence 87 (2007) 164-174
18. Knudsen H.K., Ducharme L.J., Roman P.M., and Link T. Buprenorphine diffusion: The attitudes of substance abuse treatment counselors. Journal of Substance Abuse Treatment 29 (2005) 95-106
19. Kranzler H.R., and Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: A meta-analysis. Alcoholism: Clinical and Experimental Research 25 (2001) 1335-1341
20. Lind, C. (2007). Introduction of a new pharmacotherapy program at Hazelden: Challenges and solutions. Paper presented at the Addiction Health Services Research Conference, Athens, GA.
21. Ling W., Amass L., Shoptow M., Annon J.J., Hillhouse M., Babcock D., et al. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: Findings from the National Institute on Drug Abuse's Clinical Trials Network. Addiction 100 (2005) 1090-1100
22. Ling W., Charuvastra C., Collins J.F., Batki S., Brown L.S., Kintaudi P., et al. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomized clinical trial. Addiction 93 (1998) 475-486
23. Ling W., Rawson R.A., and Anglin M.D. Pharmacology, practice, and politics: A tale of two opiate pharmacotherapies. In: Sorensen J.L., Rawson R.A., Guydish J., and Zweben J.E. (Eds). Drug abuse treatment through collaboration: Practice and research that work (2003), American Psychological Association, Washington, DC
24. Longshore D., Annon J., Anglin M.D., and Rawson R.A. Levo-alpha-acetylmethadol (LAAM) versus methadone: Treatment retention and opiate use. Addiction 100 (2003) 1131-1139
25. Mark T.L., Kranzler H.R., Poole V.H., Hagen C.A., McLeod C., and Crosse S. Barriers to the use of medications to treat alcoholism. The American Journal on Addictions 12 (2003) 281-294
26. Mark T.L., Kranzler H.R., and Song X. Understanding U.S. addiction physicians' low rate of naltrexone prescription. Drug and Alcohol Dependence 71 (2003) 219-228
27. Mark T.L., Kranzler H.R., Song X., Bransberger P., Poole V.H., and Crosse S. Physicians' opinions about medications to treat alcoholism. Addiction 98 (2003) 617-626
28. Marsch L.A. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: A meta-analysis. Addiction 93 (1998) 515-532
29. Mason B.J. Acamprosate in the treatment of alcohol dependence. Expert Opinion on Pharmacotherapy 12 (2005) 2103-2115
30. McCarty D., Fuller B.E., Arfken C., Miller M., Nunes E.V., Edmundson E., et al. Direct care workers in the national drug abuse treatment clinical trials network: Characteristics, opinions, and beliefs. Psychiatric Services 58 (2007) 181-190
31. McCarty D., Fuller B.E., Kaskutas L.A., Wendt B., Nunes E.V., Miller M., et al. Treatment programs in the National Drug Abuse Treatment Clinical Trials Network. Drug and Alcohol Dependence 92 (2008) 200-207
32. Miller W.R., and Wilbourne P.L. Mesa Grande: A methodological analysis of clinical trials of treatments for alcohol use disorders. Addiction 97 (2002) 265-277
33. National Consensus Development Panel on Effective Treatment of Opiate Addiction. Effective medical treatment of opiate addiction. JAMA: Journal of the American Medical Association 280 (1998) 1936-1943
34. National Institutes of Health. Effective medical treatment of opiate addiction (NIH Consensus Development Conference Statement) (1997, November 17-19). http://consensus.nih.gov/1997/1998TreatOpiateAddiction108html.htm Retrieved November 3, 2005, from http://consensus.nih.gov/1997/1998TreatOpiateAddiction108html.htm
35. Ogborne A.C., Wild T.C., Braun K., and Newton-Taylor B. Measuring treatment process beliefs among staff of specialized addiction treatment services. Journal of Substance Abuse Treatment 15 (1998) 301-312
36. O'Malley S.S., Jaffe A.J., Chang G., Shottenfeld R.S., Meyer R.E., and Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence: A controlled study. Archives of General Psychiatry 49 (1992) 881-887
37. Pani P.P., Maremmani I., Pirastu R., Tagliamonte A., and Gessa G.L. Buprenorphine: A controlled clinical trial in the treatment of opioid dependence. Drug and Alcohol Dependence 60 (2000) 39-50
38. Power E.J., Nishimi R.Y., and Kizer K.W. Evidence-based treatment practices for substance use disorders: Workshop proceedings (2005), National Quality Forum, Washington, DC
39. Raudenbush S., and Bryk A. Hierarchical linear models: Applications and data analysis methods. 2nd ed. (2002), Sage, Thousand Oaks, CA
40. Rawson R.A., Hasson A.L., Huber A.M., McCann M.J., and Ling W. A 3-year progress report on the implementation of LAAM in the United States. Addiction 93 (1998) 533-540
41. Roman P.M., and Johnson J.A. Adoption and implementation of new technologies in substance abuse treatment. Journal of Substance Abuse Treatment 22 (2002) 211-218
42. Simpson D.D. A conceptual framework for transferring research to practice. Journal of Substance Abuse Treatment 22 (2002) 171-182
43. Snijders T., and Bosker R. Multilevel analysis: An introduction to basic and advanced multilevel modeling (1999), Sage, London
44. Substance Abuse and Mental Health Services Administration. National survey of substance abuse treatment services (N-SSATS): 2000. Data on substance abuse treatment facilities (2002), Author, Rockville, MD
45. Thomas C.P., Wallack S.S., Lee S., McCarty D., and Swift R. Research to practice: Adoption of naltrexone in alcoholism treatment. Journal of Substance Abuse Treatment 24 (2003) 1-11
46. Volpicelli J.R., Alterman A.I., Hayashida M., and O'Brien C.P. Naltrexone in the treatment of alcohol dependence. Archives of General Psychiatry 49 (1992) 876-880